Chengdu Mingde Zhiyuan Pharmaceutical Technology

Chengdu Mingde Zhiyuan Pharmaceutical Technology is a clinical-stage biotechnology company based in Chengdu, China, specializing in the discovery and development of innovative small molecule drugs. The company leverages its proprietary Proteolysis Targeting Chimera (PROTAC) platform to develop next-generation therapies for oncology and other unmet medical needs. Its lead programs focus on overcoming resistance in B-cell malignancies and lung cancer by targeting key proteins like BTK and ALK. Founded by industry veterans with extensive experience at global pharmaceutical firms, the company aims to bridge the gap between basic research and clinical application through efficient drug design and optimization.